FDA Pauses Regeneron/Teva Painkiller Study

Opioid-alternative fasinumab gets halted during mid-stage trial due safety concerns.

Fasinumab study halted by FDA / Photo: FierceBiotech
Fasinumab study halted by FDA / Photo: FierceBiotech

An October 17th Reuters article reported the FDA has placed a hold on studies for a new pain-drug from Regeneron and Teva. The injectable painkiller, fasinumab, is designed to block nerve growth factor, but was linked to joint damage in a patient with advanced osteoarthritis during trials.

The two drug companies plan to seek the FDA’s blessing for a late-stage study on similar patients, excluding those with advanced osteoarthritis. The delay suggests fasinumab may be vulnerable to the same setbacks as other drugs in its class including heightened scrutiny, repeated delays, and labeling restrictions. Should fasinumab make it to market, it could be a highly lucrative alternative to prescription opioids without the high rates of addiction, overdose, and death.

Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
Researched List: Blister Machines for Life Sciences
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report